0001193125-23-241849.txt : 20230926 0001193125-23-241849.hdr.sgml : 20230926 20230926073428 ACCESSION NUMBER: 0001193125-23-241849 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230926 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230926 DATE AS OF CHANGE: 20230926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001746473 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474272481 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39303 FILM NUMBER: 231277164 BUSINESS ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-481-6770 MAIL ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d473253d8k.htm 8-K 8-K
false 0001746473 0001746473 2023-09-26 2023-09-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2023

 

 

PLIANT THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39303   47-4272481

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

260 Littlefield Avenue,  
South San Francisco, CA   94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 481-6770

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   PLRX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events.

On September 26, 2023, Pliant Therapeutics, Inc. (the “Company”) announced positive data from INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis and suspected moderate to severe liver fibrosis. The trial met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose. The trial’s exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis (“ELF”) score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging of the liver. Results at the initial three doses tested showed bexotegrast reduced both ELF scores and PRO-C3 levels at Week 12 at all doses relative to placebo with statistically significant differences at the 160 mg dose relative to placebo at Week 12. Patients also showed stabilization of liver chemistry, including a dose-dependent trend in reduction of alkaline phosphatase levels, relative to placebo at Week 12. In addition, preliminary MRI imaging results suggest improved hepatocyte function and bile flow with bexotegrast 160 mg. A copy of the Company’s press release, titled “Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis,” is attached as Exhibit 99.1 to this Current Report and is incorporated by reference herein.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

No.

    Description
99.1    Press Release, dated September 26, 2023, titled “Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis.”
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PLIANT THERAPEUTICS, INC.
Date: September 26, 2023   By:  

/s/ Keith Cummings

    Keith Cummings, M.D., MBA
        Chief Financial Officer
 EX-99.1 2 d473253dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events

Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose

Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12

Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET

SOUTH SAN FRANCISCO, CA., September 26, 2023 — Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced positive data from INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The trial met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose. The trial’s exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging (MRI) of the liver. Results at the initial three doses tested showed bexotegrast reduced both ELF scores and PRO-C3 levels at Week 12 at all doses relative to placebo with statistically significant differences at the 160 mg dose relative to placebo at Week 12. Patients also showed stabilization of liver chemistry, including a dose-dependent trend in reduction of alkaline phosphatase (ALP) levels, relative to placebo at Week 12. In addition, preliminary MRI imaging results suggest improved hepatocyte function and bile flow with bexotegrast 160 mg. Twelve-week interim data from the high-dose 320 mg cohort is expected in the first quarter of 2024.

INTEGRIS-PSC is a multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2a trial evaluating bexotegrast at once-daily doses of 40 mg, 80 mg, 160 mg or placebo for 12 weeks in 85 patients with PSC. 64 patients were enrolled in the active arms and 21 patients were enrolled in the placebo arm. We believe INTEGRIS-PSC to be the first randomized clinical trial to use an enrichment strategy to enroll patients with suspected moderate to severe liver fibrosis based on liver stiffness measure, ELF score or historical liver biopsy. Baseline characteristics of the trial population reflected this enrichment.

“The INTEGRIS-PSC interim data has surpassed our expectations, providing hope to patients with PSC who currently have no approved therapeutic options available to them,” said Éric Lefebvre, M.D., Chief Medical Officer of Pliant. “Today marks a new chapter for the bexotegrast platform, having now shown meaningful antifibrotic effects across multiple tissues and indications. The INTEGRIS-PSC and INTEGRIS-

IPF trials provide further evidence that localized inhibition of TGF-ß by bexotegrast blocks a profibrotic pathway that is common in multiple fibrotic diseases without affecting TGF-ß signaling systemically. This, coupled with the favorable safety and tolerability profile seen to date, gives us great confidence in bexotegrast as we look to broaden future development into additional pulmonary and liver indications.”

Bexotegrast Was Well Tolerated Across All Doses

The primary endpoint of the INTEGRIS-PSC trial is the evaluation of the safety and tolerability of bexotegrast. The secondary endpoint is an assessment of its pharmacokinetics.

Bexotegrast was well tolerated at all three doses tested. Of the 64 patients treated with bexotegrast, 60 (94%) completed 12 weeks of treatment with no deaths or drug-related severe or serious adverse events (SAE). Most treatment emergent adverse events (TEAEs) were mild or moderate in severity and consistent with PSC disease symptoms. Patients in the trial who had concomitant inflammatory bowel disease (IBD) saw no change in their IBD symptoms as measured by partial Mayo Score while on treatment.

Bexotegrast total and unbound plasma concentrations increased with dose.

Bexotegrast Demonstrated Antifibrotic Activity in a PSC Population with Suspected Moderate to Severe Liver Fibrosis at Week 12

The exploratory endpoints of the INTEGRIS-PSC trial include changes in liver fibrosis markers, ELF and PRO-C3, liver biochemistry and MRI imaging.

 

LOGO

ELF: enhanced liver fibrosis score; All participants had baseline ELF > 7.7 (moderate to severe liver fibrosis)2

1 Hepatology 2015 62(1):188-197 2 Hepatology 2015 62(1):188-197

Figure 1. Change in ELF Score at 12 Weeks in INTEGRIS-PSC

A treatment effect was observed on ELF score in all bexotegrast dose groups. The ELF score is a well-established prognostic marker of liver disease severity and liver-related events in patients with advanced fibrosis.1 ELF is strongly associated with transplant-free survival in PSC and may be useful as a surrogate marker in clinical trials.2 Bexotegrast reduced ELF scores relative to placebo at all doses, with a statistical significance achieved at the 160 mg dose. The bexotegrast 160 mg dose group demonstrated an 84% reduction of the change in ELF score relative to placebo at Week 12. Importantly, at the 160 mg dose group, statistically significant reductions were observed across all three components of the ELF score (tissue inhibitor of metalloproteinase 1 (TIMP-1), procollagen III N-terminal propeptide (PIIINP) and hyaluronic acid (HA)). Similarly, the bexotegrast 160 mg dose showed a statistically significant reduction in PRO-C3 level relative to placebo at Week 12. PRO-C3 is a biomarker of active fibrogenesis with higher levels associated with greater disease activity.3

Patients with PSC tend to have elevated or fluctuating liver biochemistry levels.4 Patients treated with bexotegrast showed stabilization of liver chemistry levels, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as total and direct bilirubin, at all doses versus increases in placebo at Week 12. Additionally, bexotegrast-treated patients with elevated baseline ALP levels (ie, > upper limit of normal) showed a dose-dependent trend in reduction in ALP relative to placebo at Week 12.

Preliminary MRI imaging of the liver using gadoxedate contrast showed small increases in MRI relative enhancement from baseline across all dose groups, compared to a decrease observed in the placebo group to Week 12. MRI relative enhancement using gadoxedate contrast is a measure of hepatocyte function, with increased enhancement suggesting improved hepatocyte function.5,6 Similarly, the change in time of arrival of gadoxedate in the common bile duct from baseline to Week 12 was shorter in the bexotegrast arms compared to the placebo group. Time to arrival is a measure of bile flow with shorter times suggestive of improved bile flow.7

Patients with PSC often experience pruritus, or itch, as part of their disease.8 Treatment with bexotegrast demonstrated dose dependent reductions in the Itch Numerical Rating Scale relative to placebo with statistical significance achieved at the 160 mg dose at Week 12.

“The INTEGRIS-PSC data is compelling, with bexotegrast demonstrating a favorable tolerability profile, and showing antifibrotic activity across all doses,” said Cynthia Levy, M.D., Professor of Medicine at the University of Miami School of Medicine, and INTEGRIS-PSC trial investigator. “I am encouraged by the clear reduction in serum ELF score, a well-established prognostic biomarker in PSC, at all doses compared to placebo. Given the lack of pharmaceutical treatment options, our imperative is to identify novel therapies that slow or prevent disease progression. I look forward to seeing additional data from INTEGRIS-PSC.”

 

1 

Vesterhus M, et al. Hepatology. 2015 Jul;62(1):188-97.

2 

Bowlus CL, et al. Hepatology. 2023 Feb 1;77(2):659-702.

3 

Nielsen MJ, et al. Aliment Pharmacol Ther. 2018 Jul;48(2):179-189.

4 

Karlsen TH, et al. J Hepatol. 2017 Dec;67(6):1298-1323.

5 

Schulze J, et al. Clin Gastroenterol Hepatol. 2019 Jan;17(1):192-199.

6 

Nilsson H, et al. J Magn Reson Imaging. 2014 Apr;39(4):879-86.

7 

Elkilany A, et al. Abdom Radiol (NY). 2021 Mar;46(3):979-991.

8 

Karlsen TH, et al. J Hepatol. 2017 Dec;67(6):1298-1323.

INTEGRIS-PSC Next Steps

Pliant has recently completed enrollment of the high-dose 320 mg dose cohort of the INTEGRIS-PSC Phase 2a trial. Interim 12-week data from the 320 mg dose is expected in the first quarter of 2024, with 24-week data from this dose expected in mid-2024.

We would like to thank our INTEGRIS-PSC investigators and their study teams for their dedication in support of the successful execution of this trial. Special thanks to the INTEGRIS-PSC clinical trial participants, their families and support networks for helping us advance this promising program.

INTEGRIS-PSC Multinational Phase 2 Trial of Bexotegrast (NCT04480840)

INTEGRIS-PSC is a Phase 2a, randomized, dose-ranging, double-blind, placebo-controlled trial evaluating the safety, tolerability, and pharmacokinetics of bexotegrast administered over 12 weeks in patients with IPF. Patients were enrolled in doses of 40 mg, 80 mg, 160 mg or 320 mg, with a 3:1 randomization ratio (active:placebo) and stratification based on use of ursodeoxycholic acid (UDCA). The primary endpoint is the evaluation of bexotegrast safety and tolerability and the secondary endpoint is the assessment of pharmacokinetics across a dose range. Exploratory endpoints will measure changes in liver fibrosis markers, ELF and PRO-C3, liver biochemistry and liver imaging.

Background on Primary Sclerosing Cholangitis

PSC is a rare, progressive liver disease of unknown origin, which frequently occurs in the setting of inflammatory bowel disease. PSC affects more than 30,000 patients in the United States and over 100,000 patients worldwide. The disease can occur in all ages, gender, and race. PSC is characterized by inflammation and fibrosis, with progressive liver and biliary damage leading to cirrhosis and liver failure. Currently there are no FDA or EMA-approved therapies for patients with PSC. Therefore, there is a high unmet need for new therapeutic options to address the symptoms and modify the disease progression of this grievous illness.

Conference Call and Webcast

The Company will host a conference call and webcast with a slide presentation today, Tuesday September 26 at 8:00 a.m. ET to discuss this update. Interested parties may access the live webcast on Pliant’s website at Pliant Therapeutics INTEGRIS-PSC Webcast or may participate via telephone by registering in advance at the following link: Pliant Therapeutics INTEGRIS-PSC Conference Call. Upon registration, all telephone participants will receive the dial-in number along and a unique passcode to access the call. An archived replay of the webcast will be available on Pliant’s website for 60 days following completion of the event.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing

cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. Pliant has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis. Pliant has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition to clinical stage programs, Pliant currently has a preclinical program targeting muscular dystrophies. For additional information, please visit: www.PliantRx.com. Follow us on social media Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding the safety, tolerability, pharmacodynamics and therapeutic potential of bexotegrast; our plans for the future development of bexotegrast; bexotegrast’s potential to become a treatment for IPF or PSC; the anticipated timing of data and progress from our clinical studies; including the timing of 12-week and 24-week data from the 320 mg dose cohort of the INTEGRIS-PSC Phase 2a trial in the first quarter of 2024 and mid-2024, respectively. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic and marketplace conditions, our reliance on third parties for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the period ended June 30, 2023 which is available on the SEC’s website at www.sec.gov. Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Investor and Media Contact:

Christopher Keenan

Vice President, Investor Relations and Corporate Communications

Pliant Therapeutics, Inc.

ir@pliantrx.com

EX-101.SCH 3 plrx-20230926.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 plrx-20230926_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 plrx-20230926_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g473253g0926084738605.jpg GRAPHIC begin 644 g473253g0926084738605.jpg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g473253g0926084738867.jpg GRAPHIC begin 644 g473253g0926084738867.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Sep. 26, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001746473
Document Type 8-K
Document Period End Date Sep. 26, 2023
Entity Registrant Name PLIANT THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39303
Entity Tax Identification Number 47-4272481
Entity Address, Address Line One 260 Littlefield Avenue
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 481-6770
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol PLRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 d473253d8k_htm.xml IDEA: XBRL DOCUMENT 0001746473 2023-09-26 2023-09-26 false 0001746473 8-K 2023-09-26 PLIANT THERAPEUTICS, INC. DE 001-39303 47-4272481 260 Littlefield Avenue South San Francisco CA 94080 (650) 481-6770 false false false false Common Stock, par value $0.0001 per share PLRX NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d473253d8k.htm plrx-20230926.xsd plrx-20230926_lab.xml plrx-20230926_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d473253d8k.htm": { "nsprefix": "plrx", "nsuri": "http://www.pliantrx.com/20230926", "dts": { "inline": { "local": [ "d473253d8k.htm" ] }, "schema": { "local": [ "plrx-20230926.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "plrx-20230926_lab.xml" ] }, "presentationLink": { "local": [ "plrx-20230926_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "report": { "R1": { "role": "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-09-26_to_2023-09-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d473253d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-09-26_to_2023-09-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d473253d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.pliantrx.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001193125-23-241849-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-241849-xbrl.zip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end